|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lynch TJ, Bell DW, Sordella R, et al:
Activating mutations in the epidermal growth factor receptor
underlying responsiveness of non-small-cell lung cancer to
gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Paez JG, Janne PA, Lee JC, et al: EGFR
mutations in lung cancer: correlation with clinical response to
gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Soda M, Choi YL, Enomoto M, et al:
Identification of the transforming EML4-ALK fusion gene in
non-small-cell lung cancer. Nature. 448:561–566. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Maemondo M, Inoue A, Kobayashi K, et al:
Gefitinib or chemotherapy for non-small-cell lung cancer with
mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mitsudomi T, Morita S, Yatabe Y, et al:
Gefitinib versus cisplatin plus docetaxel in patients with
non-small-cell lung cancer harbouring mutations of the epidermal
growth factor receptor (WJTOG3405): an open label, randomised phase
3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar
|
|
7
|
Shaw AT, Kim DW, Nakagawa K, et al:
Crizotinib versus chemotherapy in advanced ALK-positive lung
cancer. N Engl J Med. 368:2385–2394. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Scagliotti GV, Parikh P, von Pawel J, et
al: Phase III study comparing cisplatin plus gemcitabine with
cisplatin plus pemetrexed in chemotherapy-naive patients with
advanced-stage non-small-cell lung cancer. J Clin Oncol.
26:3543–3551. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sandler A, Gray R, Perry MC, et al:
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell
lung cancer. N Engl J Med. 355:2542–2550. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Arriagada R, Bergman B, Dunant A, Le
Chevalier T, Pignon JP and Vansteenkiste J: Cisplatin-based
adjuvant chemotherapy in patients with completely resected
non-small-cell lung cancer. N Engl J Med. 350:351–360. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Winton T, Livingston R, Johnson D, et al:
Vinorelbine plus cisplatin vs. observation in resected
non-small-cell lung cancer. N Engl J Med. 352:2589–2597. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Douillard JY, Rosell R, De Lena M, et al:
Adjuvant vinorelbine plus cisplatin versus observation in patients
with completely resected stage IB-IIIA non-small-cell lung cancer
(Adjuvant Navelbine International Trialist Association (ANITA)): a
randomised controlled trial. Lancet Oncol. 7:719–727. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Olaussen KA, Fouret P and Kroemer G:
ERCC1-specific immunostaining in non-small-cell lung cancer. N Engl
J Med. 357:1559–1561. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zheng Z, Chen T, Li X, Haura E, Sharma A
and Bepler G: DNA synthesis and repair genes RRM1 and ERCC1 in lung
cancer. N Engl J Med. 356:800–808. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Friboulet L, Olaussen KA, Pignon JP, et
al: ERCC1 isoform expression and DNA repair in non-small-cell lung
cancer. N Engl J Med. 368:1101–1110. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Drilon A, Rekhtman N, Ladanyi M and Paik
P: Squamous-cell carcinomas of the lung: emerging biology,
controversies, and the promise of targeted therapy. Lancet Oncol.
13:e418–e426. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Paul KP, Adnan H, Lu W, Natasha R, Marc L
and Mark GK: Multiplex testing for driver mutations in squamous
cell carcinomas of the lung. J Clin Oncol. 30(Suppl): 75052012.
|
|
18
|
The Cancer Genome Atlas Research Network.
Comprehensive genomic characterization of squamous cell lung
cancers. Nature. 489:519–525. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kim TJ, Lee JW, Song SY, et al: Increased
expression of pAKT is associated with radiation resistance in
cervical cancer. Br J Cancer. 94:1678–1682. 2006.PubMed/NCBI
|
|
20
|
Yamamoto H, Shigematsu H, Nomura M, et al:
PIK3CA mutations and copy number gains in human lung cancers.
Cancer Res. 68:6913–6921. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hussenet T, Dali S, Exinger J, et al: SOX2
is an oncogene activated by recurrent 3q26.3 amplifications in
human lung squamous cell carcinomas. PLoS One. 5:e89602010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hammerman PS, Sos ML, Ramos AH, et al:
Mutations in the DDR2 kinase gene identify a novel therapeutic
target in squamous cell lung cancer. Cancer Discov. 1:78–89. 2011.
View Article : Google Scholar
|
|
23
|
McCarty KS Jr, Miller LS, Cox EB, Konrath
J and McCarty KS Sr: Estrogen receptor analyses. Correlation of
biochemical and immunohistochemical methods using monoclonal
antireceptor antibodies. Arch Pathol Lab Med. 109:716–721.
1985.PubMed/NCBI
|
|
24
|
Engelman JA, Luo J and Cantley LC: The
evolution of phosphatidylinositol 3-kinases as regulators of growth
and metabolism. Nat Rev Genet. 7:606–619. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Samuels Y, Wang Z, Bardelli A, et al: High
frequency of mutations of the PIK3CA gene in human cancers.
Science. 304:5542004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Karakas B, Bachman KE and Park BH:
Mutation of the PIK3CA oncogene in human cancers. Br J Cancer.
94:455–459. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Campbell IG, Russell SE, Choong DY, et al:
Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer
Res. 64:7678–7681. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Massion PP, Kuo WL, Stokoe D, et al:
Genomic copy number analysis of non-small cell lung cancer using
array comparative genomic hybridization: implications of the
phosphatidylinositol 3-kinase pathway. Cancer Res. 62:3636–3640.
2002.PubMed/NCBI
|
|
29
|
Kawano O, Sasaki H, Endo K, et al: PIK3CA
mutation status in Japanese lung cancer patients. Lung Cancer.
54:209–215. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ji M, Guan H, Gao C, Shi B and Hou P:
Highly frequent promoter methylation and PIK3CA amplification in
non-small cell lung cancer (NSCLC). BMC Cancer. 11:1472011.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lu Y, Futtner C, Rock JR, et al: Evidence
that SOX2 overexpression is oncogenic in the lung. PLoS One.
5:e110222010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tompkins DH, Besnard V, Lange AW, et al:
Sox2 is required for maintenance and differentiation of bronchiolar
Clara, ciliated, and goblet cells. PLoS One. 4:e82482009.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sholl LM, Long KB and Hornick JL: Sox2
expression in pulmonary non-small cell and neuroendocrine
carcinomas. Appl Immunohistochem Mol Morphol. 18:55–61. 2010.
View Article : Google Scholar
|
|
34
|
Bass AJ, Watanabe H, Mermel CH, et al:
SOX2 is an amplified lineage-survival oncogene in lung and
esophageal squamous cell carcinomas. Nat Genet. 41:1238–1242. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Velcheti V, Schalper K, Yao X, et al: High
SOX2 levels predict better outcome in non-small cell lung
carcinomas. PLoS One. 8:e614272013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Brcic L, Sherer CK, Shuai Y, Hornick JL,
Chirieac LR and Dacic S: Morphologic and clinicopathologic features
of lung squamous cell carcinomas expressing Sox2. Am J Clin Pathol.
138:712–718. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chen S, Xu Y, Chen Y, et al: SOX2 gene
regulates the transcriptional network of oncogenes and affects
tumorigenesis of human lung cancer cells. PLoS One. 7:e363262012.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hussenet T and du Manoir S: SOX2 in
squamous cell carcinoma: amplifying a pleiotropic oncogene along
carcinogenesis. Cell Cycle. 9:1480–1486. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Toyooka S, Matsuo K, Shigematsu H, et al:
The impact of sex and smoking status on the mutational spectrum of
epidermal growth factor receptor gene in non small cell lung
cancer. Clin Cancer Res. 13:5763–5768. 2007. View Article : Google Scholar : PubMed/NCBI
|
